Tegoprubart Shows Kidney Benefit in Phase 2 Trial
The investigational drug outperformed tacrolimus in preserving organ function for first-time transplant recipients.
Updated on Oct. 24, 2026 in Stroke
Live Poll
Are you confident that new medical therapies will successfully reduce side effects from current long-term treatments?
The Phase 2 BESTOW clinical trial found that tegoprubart better preserves kidney function in first-time transplant recipients compared to tacrolimus. The drug also showed superior health-related quality of life improvements at week 52.
Why it matters
Tegoprubart potentially offers a new standard of care for immunosuppression by targeting the CD40L pathway to improve long-term graft outcomes. This development could reshape treatment protocols for patients undergoing their first kidney transplant.
The BESTOW trial enrolled 127 treated patients, with 51 receiving tegoprubart and 56 receiving tacrolimus. Researchers noted statistically significant kidney function benefits at 18 months.
The players
University of Minnesota Medical School
This institution is the academic home of the corresponding author who oversaw the clinical research.
The details
Tegoprubart functions by targeting the CD40L pathway, leading to stabilized kidney graft function after the first month. Patients on the new therapy reported improvements across all five health-related quality of life subscales, compared to four out of five for those on tacrolimus.
Timeline
Findings were presented at ASN Kidney Week 2026 from October 22-25, 2026.
Health-related quality of life was assessed at week 52.
Statistical significance of kidney function benefit was measured at 18 months.
Health Landscape
The presentation of study findings at the ASN Kidney Week 2026 conference marks a new milestone in nephrology research. These trial results extend the current medical understanding by demonstrating the viability of CD40L pathway inhibition in transplant medicine.
Patients may eventually see a shift in standard immunosuppression protocols following a successful transition from tacrolimus to newer therapies. This could lead to improved long-term organ health and better quality of life scores for individuals undergoing initial kidney transplants.
The takeaway
Tegoprubart demonstrates a potential shift in transplant care by offering better kidney function preservation than traditional treatments. Patients and providers should watch for future clinical trial data to confirm the drug's long-term utility in wider populations.
Further reading
For more information on current developments in organ health, visit the Stroke section.
Live Poll
Are you confident that new medical therapies will successfully reduce side effects from current long-term treatments?
